# GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

> **NCT00925873** · PHASE3 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 303 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Active comparator (no fludarabine)
- **DRUG:** Experimental (fludarabine)

## Key facts

- **NCT ID:** NCT00925873
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-06
- **Primary completion:** 2000-04
- **Final completion:** 2004-11
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2009-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925873, "GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00925873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*